fda compounding semaglutide warning october 2025 Bad news: You may get cut off from your GLP-1 this week… FDA Issues Warning: Compounding Certain
Description
Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD
Explore the benefits of GLP-1 weight loss treatments with Hormone Fitness
GLP-1 Support helps support appetite control, cravings, and metabolic balance so energy feels steadier and fullness feels more natural throughout the day
No artificial dyes, emulsifiers, or flavors
Hyderabad-based Natco Pharma has sued Novo Nordisk, arguing its semaglutide (Wegovy) version doesnt infringe device/process patents
Obstructive sleep apnea (OSA) is strongly associated with obesity, and weight loss is a cornerstone of its management
